首页|期刊导航|中国中西医结合杂志|基于网状Meta分析愈心痛胶囊治疗冠心病心绞痛药物经济学评价

基于网状Meta分析愈心痛胶囊治疗冠心病心绞痛药物经济学评价OA

Cost-Effectiveness Analysis of Yuxintong Capsule for Coronary Heart Disease Angina Pectoris Based on Network Meta-Analysis

中文摘要英文摘要

目的 评价愈心痛胶囊治疗冠心病心绞痛的药物经济学.方法 采用成本-效果分析方法,结合网状Meta分析所得疗效数据,计算愈心痛胶囊、对照药B和对照药A的增量成本-效果比(ICER),应用TreeAge Pro软件构建决策树模型,进行基础分析和敏感性分析.结果 以心绞痛发作次数为指标时,愈心痛胶囊相较于对照药B和对照药A的ICER分别为468.62元/次和971.65元/次,均低于意愿支付阈值(WTP,以2023年人均可支配收入的10%计算,即3 921.8元),显示其更具经济性.以心绞痛持续时间为指标时,愈心痛胶囊相较于对照药B和对照药A的ICER分别为952.55元/min和1 932.00元/min,虽仍低于WTP,但愈心痛胶囊较对照药A仅减少0.86 min.单因素敏感性分析与概率敏感性分析结果表明基础分析结果稳健.结论 在减少心绞痛发作次数方面,愈心痛胶囊联合常规治疗显示出更优经济性;而在缩短心绞痛持续时间方面,因临床获益有限,尚需进一步研究验证.

Objective To evaluate the pharmacoeconomics of Yuxintong Capsule in the treatment of coronary heart disease angina pectoris.Methods A cost-effectiveness analysis was adopted,combining efficacy data derived from a network meta-analysis.The incremental cost-effectiveness ratios(ICER)of Yuxintong Capsule compared with control drug B and control drug A were calculated.A decision tree model was constructed using TreeAge Pro software,and both base-case and sensitivity analyses were conducted.Results When the frequency of angina attacks was used as the outcome measure,the ICER of Yuxintong Capsule compared with control drug B and control drug A were 468.62 CNY/attack and 971.65 CNY/attack,respectively,both below the willingness-to-pay(WTP)threshold(calculated as 10%of the 2023 per capita disposable income,i.e.,3 921.8 CNY),indicating that Yuxintong Capsule was more cost-effective.When the duration of angina attacks was used as the outcome measure,the ICER of Yuxintong Capsule compared with control drug B and control drug A were 952.55 CNY/min and 1 932.00 CNY/min,respectively.Although still below the WTP threshold,Yuxintong Capsule reduced the duration by only 0.86 minutes compared with control drug A.Both one-way sensitivity analysis and probabilistic sensitivity analysis indicated that the base-case results were robust.Conclusions In terms of reducing the frequency of angina attacks,Yuxintong Capsule combined with conventional therapy demonstrates superior cost-effectiveness.However,regarding the shortening of the duration of angina attacks,due to limited clinical benefit,further research is warranted to validate its cost-effectiveness.

赵瑞霞;乔利杰;皮哲宇;郭红鑫;栗蕊;邢云飞;李彬

河南中医药大学第一附属医院河南省中医药循证医学中心办公室(郑州 450046)河南中医药大学第一附属医院河南省中医药循证医学中心办公室(郑州 450046)||河南中医药大学第一附属医院心脏中心(郑州 450046)河南中医药大学第一临床医学院(郑州 450000)河南中医药大学第一临床医学院(郑州 450000)河南中医药大学第一附属医院河南省中医药循证医学中心办公室(郑州 450046)河南中医药大学第一附属医院河南省中医药循证医学中心办公室(郑州 450046)河南中医药大学第一附属医院河南省中医药循证医学中心办公室(郑州 450046)||河南中医药大学第一附属医院心脏中心(郑州 450046)

愈心痛胶囊冠心病心绞痛药物经济学网状Meta分析

Yuxintong Capsulecoronary heart diseaseangina pectorispharmacoeconomicsnetwork meta-analysis

《中国中西医结合杂志》 2026 (8)

909-915,7

中华中医药学会研究与评价专项课题(No.CACMRE2024-A-03)

10.7661/j.cjim.20260706.147

评论